| Excerpt | Reference |
|---|
| "Evaporative dry eye is often secondary to meibomian gland disease and results in a defective lipid layer." | ( Collum, LM; O'Brien, PD, 2004) |
| "Dry eye disease is a common and often underdiagnosed condition that affects > 10% of the adult population, > 65 years of age in the US." | ( Donnenfeld, ED; Perry, HD, 2004) |
| "Dry eye is an under-diagnosed ocular disorder." | ( Malik, P; Sahai, A, 2005) |
| "Therapy of dry eye is usually based upon topical administration of tear substitutes; estrogen or androgen-based eye drops represents a promising innovative treatment based upon important scientific rationale." | ( Campos, EC; Versura, P, 2005) |
| "Dry eye is a very common ocular disease characterized by eye dryness and photophobia." | ( Chang, YH; Li, WC; Lin, HJ, 2005) |
| "Dry eye disease is a common debilitating ocular disease." | ( Asbell, PA; Fahim, MM; Fan, VC; Haji, S; Koonapareddy, CV, 2006) |
| "Dry eye is the most common reason for contact lens (CL) discontinuation, and the patient with pre-existing dry eye presents particular challenges to the CL fitter." | ( Longmuir, RA; Sindt, CW, 2007) |
| "Dry eye disease is a common and increasingly prevalent condition particularly associated with advancing age and postmenopausal women." | ( Foulks, GN, 2008) |
| "Patients with dry eye are more likely to have fluoroquinolone-resistant conjunctival bacteria than controls." | ( Hori, Y; Inoue, T; Koh, S; Maeda, N; Sakamoto, M; Tano, Y, 2008) |
| "Dry eye is a potent stimulus of both innate and adaptive immune systems." | ( de Paiva, CS; Li, DQ; Pflugfelder, SC; Stern, ME, 2008) |
| "Dry eye disease is one of the most commonly encountered conditions in eye care, and inflammation is a frequent finding." | ( Ridder, WH, 2008) |
| "In conclusion, dry eye is more common at high altitude, particularly in the native population." | ( D'Souza, P; Gupta, N; Himashree, G; Prasad, I, 2008) |
| "Dry eyes are treated by instillation of eye drops of cyclosporine A emulsion or by punctal plug insertion in canaliculus to block tear drainage." | ( Chauhan, A; Gupta, C, 2011) |
| "Dry eye is a chronic disease often requiring long-term management." | ( Wander, AH, 2011) |
| "Dry eye is recognized as an oxidative stress-induced disease." | ( Higuchi, A; Inoue, H; Kawakita, T; Ogishima, T; Tsubota, K, 2012) |
| "Dry eye disease is multifactorial and therefore further evaluation of the varying components of the tear film, lacrimal unit and corneal structure of these KO mice may help elucidate the role of mucins in dry eye disease." | ( Chen, Y; Evans, C; Floyd, AM; Rompala, OJ; Wang, M; Zhou, X; Zhu, L, 2012) |
| "Dry eye is often characterized by increased tear evaporation due to poor tear film quality, especially of the lipid component of the tear film." | ( Madden, LC; Simmons, PA; Tomlinson, A, 2013) |
| "Dry eye disease is a well-known late complication of radiation therapy and is often difficult to treat." | ( Hoehn, ME; Kelly, SR; Walton, RC; Wilson, MW, 2013) |
| "The prevalence of dry eye disease is high in West Bengal, Eastern India in hospital-based population." | ( Bandyopadhyay, A; Basak, S; Basak, SK; Choudhury, S; Pal, PP; Sar, S, 2012) |
| "Dry eye is commonly associated with autoimmune diseases such as Sjögren's syndrome (SS), in which exocrinopathy of the lacrimal gland leads to aqueous tear deficiency and keratoconjunctivitis sicca (KCS)." | ( Chen, FY; Chen, YT; Gallup, M; McNamara, N; Vijmasi, T, 2013) |
| "Dry eye is a significantly prevalent occupational hazard among tannery workers, severity of which increases with the age and the duration of work in tannery." | ( Gupta, RC; Khan, P; Kushwaha, RN; Mohan, S; Ranjan, R, 2014) |
| "Dry eye is a multifactorial disease of the tears and the ocular surface." | ( Chen, J; Chen, W; Deng, Y; Dong, F; Hong, J; Liu, Z; Sun, X; Xie, L; Yang, W; Zhang, M, 2014) |
| "Dry eye is one of the suggested extrahepatic complications associated with hepatitis C virus (HCV) infection." | ( Bhaskar, S; Iyer, GK; Madhavan, HN; Malathi, J; Rajalakshmy, AR, 2015) |
| "Dry eye disease is a major public health problem that affects millions of people worldwide." | ( Acharya, G; Ahmed, F; Coursey, TG; De Paiva, CS; Henriksson, JT; Isenhart, LC; Marcano, DC; Pflugfelder, SC; Shin, CS, 2015) |
| "The onset of dry eye is very common during menopause and may result from the loss of hormonal support." | ( Ebeigbe, JA; Ebeigbe, PN, 2014) |
| "Dry eye is a common disorder caused by inadequate hydration of the ocular surface that results in disruption of barrier function." | ( Argüeso, P; Bauskar, A; Fini, ME; Gleave, ME; Heur, M; Jeong, S; Kinoshita, S; Kolar, GR; Mack, WJ; Mauris, J; Moradian-Oldak, J; Nagel, BA; Nakamura, T; Panjwani, N; Pflugfelder, SC; Wilson, MR, 2015) |
| "Dry eye is a highly prevalent, chronic, and multifactorial disease that compromises quality of life and generates socioeconomic burdens." | ( Dou, Z; Du, J; Huang, Y; Liu, H; Liu, X; Meng, Z; Ru, Y; Wei, RH; Zhang, Y; Zhao, S, 2015) |
| "Dry eye is an allegedly autoimmune disorder for which the initiating mechanisms and the targeted antigens in the ocular surface are not known, yet there is extensive evidence that a localized T helper type 1 (Th1)/Th17 effector T cell response is responsible for its pathogenesis." | ( Galletti, JG; Giordano, MN; Guzmán, M; Keitelman, I; Sabbione, F; Trevani, AS, 2016) |
| "Dry eye is a common, multifactorial disease currently diagnosed by a combination of symptoms and signs." | ( Galor, A; Lanza, NL; Perez, VL; Valenzuela, F, 2016) |
| "Dry eye disease is an extremely common condition affecting millions worldwide." | ( Paton, DM, 2016) |
| "Dry eye disease is a major ophthalmologic condition with a high prevalence among the elderly." | ( Acar, N; Alassane, S; Arnould, L; Binquet, C; Bretillon, L; Bron, AM; Creuzot-Garcher, C; Delcourt, C; Ferrero, A; Muselier-Mathieu, A, 2018) |
| "Dry eye is a common eye disease, and suitable animal models are indispensable for investigating the pathogenesis and developing treatments for dry eye." | ( Li, K; Si, H; Wang, Y; Yang, Z; Zhang, C, 2017) |
| "Dry eye is defined by a tear film instability resulting in variable but systematic fluctuations in quality of vision." | ( Chamy, Y; Pisella, PJ; Vandermeer, G, 2018) |
| "Chronic dry eye is an increasingly prevalent condition worldwide, with resulting loss of visual function and quality of life." | ( Kinoshita, S; Shinomiya, K; Ueta, M, 2018) |
| "Dry eye is defined by a tear film instability resulting in variable but systematic fluctuations in the quality of vision." | ( Chamy, Y; Pisella, PJ; Vandermeer, G, 2018) |
| "Dry eye disease is a multifactorial pathology of the ocular surface." | ( Beylerian, H; Beylerian, M; Darque, A; Grimaud, F; Hoffart, L; Lazaro, M; Magalon, J; Sabatier, F; Stolowy, N; Veran, J, 2018) |
| "Dry eye is the most prominent pathology among those involving the ocular surface: a decrease of the aqueous (less frequent) or the lipid (more frequent) component of the tear film is the cause of the diminished stability of tears that is observed in this pathology." | ( Anfuso, CD; Cristaldi, M; Gagliano, C; Lupo, G; Olivieri, M; Pezzino, S; Rusciano, D, 2018) |
| "Short TBUT-type dry eye is characterized by TBUT of less than 5 seconds and dry eye symptoms such as ocular fatigue or dryness; the importance of this type has recently been gaining prominence." | ( Tsubota, K, 2018) |
| "Dry eye is one of the most common eye diseases characterized by disturbance of tear film homeostasis and a series of ocular discomforts." | ( Li, J; Liang, LY; Liu, ZG, 2019) |
| "Dry eye disease is a highly prevalent condition that causes tear film instability, ocular discomfort, and visual disturbance." | ( Hoeller, S; Knoetzl, W; Nepp, J; Prinz, A; Prinz, M, 2020) |
| "Dry eye is the most common ocular surface disease, the core pathogenesis of which is ocular surface inflammation." | ( Hu, JY; Liu, ZG; Yang, YR, 2020) |
| "A hallmark of dry eye is an unstable tear film associated with variability in objective daily measures." | ( Garcia-Queiruga, J; Garcia-Resua, C; Giraldez, MJ; Pena-Verdeal, H; Yebra-Pimentel, E, 2021) |
| "The incidence of dry eye disease is increasing worldwide because of the aging population and increasing use of information technology." | ( Imada, T; Inoue, S; Kawashima, M; Kubota, M; Kubota, S; Nakamura, S; Takemura, R; Tsubota, K; Watanabe, M, 2021) |
| "Dry eye disease is one of the most common diseases, with increasing prevalence in many countries, but treatment options are limited." | ( Jun, I; Kim, BR; Kim, TI; Lee, HK; Namkung, W; Park, J, 2021) |
| "Dry eye is a multifactorial disease of the ocular surface characterized by a loss of homeostasis of the tear film, and accompanied by ocular symptoms, in which tear film instability and hyperosmolarity, ocular surface inflammation and damage, and neurosensory abnormalities play etiological roles." | ( Zemanová, M, 2021) |
| "Dry eye is one of the most common ocular surface disorders." | ( Cruzat, A; Manzur Yarur, F; Ordenes, G, 2021) |
| "Dry eye is a multifactorial disease characterized by ocular discomfort and visual impairment." | ( Imada, T; Nakamura, S; Tani, H; Tsubota, K; Yamaga, M; Yamaki, A, 2021) |
| "Although dry eye is highly prevalent, many challenges exist in diagnosing the symptom and related diseases." | ( Anslyn, EV; Bahrami, K; Dahlhauser, SD; Jocelyn Dang, HKH; Peppas, NA; Reuther, JF; Simmonds, SP; VandeWalle, AN; Wechsler, ME; Wyse, JM, 2021) |
| "Dry eye disease is characterized by loss of tear film stability." | ( Chiu, KH; Henry, E; Hernandez-Quintela, E; Nau, JA; Quiroz-Mercado, H, 2022) |
| "Dry eye is a multifactor disease which needs comprehensive treatments to keep the homeostasis of ocular surface." | ( Kuang, G; Li, Y; Li, Z; Liang, M; Wang, H; Zhou, X, 2022) |
| "Dry eye is common in antidepressant users, but considering the ocular surface, serotonin-noradrenaline reuptake inhibitors may be more reliable than other antidepressants." | ( Celikel, G; Ismayilov, AS, 2022) |
| "Dry eye disease is one of the most common diseases with limited therapeutic options." | ( Jeon, D; Jun, I; Kim, BR; Kim, TI; Lee, HK; Namkung, W; Park, J; Ryu, K; Yoon, H, 2022) |
| "Dry eye disease is a multifactorial disorder that affects the ocular surface, with symptoms including ocular irritation, impaired vision, and pain." | ( Jerkins, G; Nau, J; Pattar, GR; Striffler, K; Torkildsen, GL, 2022) |
| "Dry Eye is one of the most common ocular diseases worldwide with an increasing number of patients." | ( Jacobi, C, 2022) |
| "Dry eye is one of the most common ocular surface diseases caused by tear film instability and ocular surface damage due to an abnormal quality or quantity of tears." | ( Chan, CL; Gao, X; Ho, CY; Hu, JM; Leung, PC; Ling, J; Tsang, SM; Wong, CK, 2022) |
| "Dry eye is a multifactorial disease that causes dryness, inflammation and damage of ocular surface." | ( Chen, Q; Qi, X; Qiao, Y; Qu, M; Zhang, B; Zhang, S; Zhou, Q, 2023) |
| "Dry eye disease is a highly prevalent ocular condition that significantly affects the quality of life and presents a major challenge in ophthalmology." | ( Chaudhari, P; Ghate, V; Lewis, SA; Nampoothiri, M; Satarker, S; Theruveethi, N; Thomas, R, 2023) |
| "Dry eye is a prevalent disorder of tear film resulting from either decreased tear production or increased tear evaporation." | ( Bhatt, RB; Patel, NH; Ranpara, KH; Shah, AT, 2023) |
| "Dry eyes are seen in two-thirds of pediatric VKC." | ( Ganesh, S; Gaur, A; Gupta, S; Rahman, M; Sangwan, VS; Tibrewal, S, 2023) |
| "Dry eye is a common condition affecting people worldwide." | ( Aparna, S; Ashwini, DL; Sah, AK, 2023) |
| "Dry eye disease is common among patients with primary Sjögren's syndrome (pSS)." | ( Bing, Z; Fang, W; Jie, X; Qihui, L; Qingqing, Z; Xinyue, H, 2023) |
| "Acupuncture for dry eye is safe." | ( Gao, WP; Jie, RP; Liu, CY; Liu, X; Zhao, N, 2023) |
| "Dry eye is a chronic ocular surface disease caused by the instability of tear film or the imbalance of the ocular surface microenvironment which can lead to a diverse range of ocular discomfort symptoms." | ( Liu, F; Long, H; Tu, N; Xiong, J; Xu, X; Zhang, R; Zhou, L; Zhou, Z, 2023) |
| Excerpt | Reference |
|---|
| "These data suggest that, in dry eyes, treatment with unpreserved artificial tears may lead to an objective improvement in corneal surface disease." | ( Göbbels, M; Spitznas, M, 1992) |
| "We describe a case of dry eye associated with Waldenström's macroglobulinemia that responded poorly to substitutive topical treatment but improved spectacularly in response to systemic chemotherapy." | ( Cordido, M; Fernández-Lago, C; Fernández-Vigo, J; López-Nieto, C, 1995) |
| "59 patients with 'dry eye condition' of various etiology were enrolled in an open multicentre study and treated 8 weeks with a new preservative-free tear substitute." | ( Feuerhake, C; Joost, P; Mayer, H; Sander, U, 1994) |
| "The treatment of dry eyes with artificial tears often fails." | ( Heiligenhaus, A; Kemper, D; Koch, JM; Kruse, FE; Waubke, TN, 1994) |
| "We are now entering a new era in dry eye treatment with the introduction of the first agent that can reverse the basic events of dry eye surface disease." | ( Gilbard, JP, 1996) |
| "Patients with severe dry eye, such as in SS, are good candidates for this treatment." | ( Shinozaki, N; Toda, I; Tsubota, K, 1996) |
| "The observed decrease suggests that dry eye disease involves immune-mediated inflammatory processes that may be decreased by treatment with topical ophthalmic cyclosporine." | ( Feuer, WJ; Ji, Z; Pflugfelder, SC; Reis, BL; Stern, M; Turner, K, 2000) |
| "Treatment of dry eye syndrome with topical cyclosporine significantly reduced the numbers of activated lymphocytes within the conjunctiva." | ( Gipson, IK; Kunert, KS; Smith, JA; Stern, ME; Tisdale, AS, 2000) |
| "We present two cases of severe dry eye in patients with chronic graft-versus-host disease (CGVHD) after hematopoietic stem cell transplantation (SCT) who were successfully treated by the systemic administration of FK506 and corticosteroids." | ( Kuwana, M; Mashima, Y; Mori, T; Nakajima, T; Ogawa, Y; Oguchi, Y; Okamoto, S; Tsubota, K; Watanabe, R; Yamada, M, 2001) |
| "Treatment of dry eye syndrome for 6 months with topical CsA resulted in an increase in goblet cell numbers in patients with NSS-KCS and SS-KCS and a decrease in epithelial turnover in those with NSS-KCS." | ( Gipson, IK; Kunert, KS; Tisdale, AS, 2002) |
| "Until recently, all treatments for dry eye have been palliative." | ( Hirsch, JD, 2003) |
| "Subjects with dry eye (n=527) were evaluated in a randomized, double-masked, parallel-group trial comparing 24 weeks of treatment with 2 concentrations of diquafosol (1% and 2%) versus placebo instilled 4 times daily." | ( Bokosky, JE; Davitt, WF; Kellerman, DJ; LaVange, LM; Mills-Wilson, MC; Nichols, KK; Schaberg, AE; Tauber, J; Yerxa, BR, 2004) |
| "Symptoms of dry eye were mild and reversible; however, abnormalities in tear dynamics and the ocular surface persisted even 6 months after discontinuation of treatment." | ( Chang, TT; Huang, FC; Lin, SC; Shih, MH; Tseng, SH, 2005) |
| "This rat dry eye model, established by repeated JB treatment in desiccating conditions, induced abnormal tear dynamics and superficial punctate keratopathy similar to that in humans." | ( Imagawa, T; Nakamura, S; Nakashima, H; Shibuya, M; Tsubota, K; Uehara, M, 2005) |
| "Therapy of dry eye is usually based upon topical administration of tear substitutes; estrogen or androgen-based eye drops represents a promising innovative treatment based upon important scientific rationale." | ( Campos, EC; Versura, P, 2005) |
| "It provides an alternative choice for dry eye treatment." | ( Chang, YH; Li, WC; Lin, HJ, 2005) |
| "Therapy of chronic dry eye disease with cyclosporine 0." | ( Barber, LD; Foulks, GN; Pflugfelder, SC; Tauber, J, 2005) |
| "Experimental dry eye (EDE) was created in C57BL6 mice, with or without or topical treatment consisting of 1% methylprednisolone, 0." | ( Corrales, RM; De Paiva, CS; Farley, WJ; Li, DQ; Pflugfelder, SC; Stern, ME; Villarreal, AL, 2006) |
| "To report a patient with dry eye after bilateral photorefractive keratectomy (PRK) with mitomycin C treatment in one eye." | ( Diakonis, VF; Ginis, H; Kymionis, GD; Pallikaris, I; Tsiklis, NS, 2006) |
| "The patient developed dry eye symptoms and superficial punctuate keratopathy in the eye treated with mitomycin C." | ( Diakonis, VF; Ginis, H; Kymionis, GD; Pallikaris, I; Tsiklis, NS, 2006) |
| "Current diagnostic tests used in dry eye disease are often neither sensitive nor reproducible, making it difficult to accurately diagnose and determine end points for clinical trials, or evaluate the usefulness of different medications in the treatment of dry eye disease." | ( Asbell, PA; Fahim, MM; Fan, VC; Haji, S; Koonapareddy, CV, 2006) |
| "Patients with dry eye disease demonstrated an increased corneal permeability and a slower rate of elimination to topically administered fluorescein when measured by the fluorophotometer." | ( Asbell, PA; Fahim, MM; Fan, VC; Haji, S; Koonapareddy, CV, 2006) |
| "Experimental dry eye (EDE) was created in C57BL/6 mice, without or with topical therapy, 1% methylprednisolone, 0." | ( Corrales, RM; De Paiva, CS; Farley, W; Li, DQ; Pflugfelder, SC; Stern, ME; Villarreal, AL, 2006) |
| "A total of 10 patients with dry eye due to LTD were treated as follows: one drop of hypotonic 0." | ( Kasetsuwan, N; Prabhasawat, P; Tesavibul, N, 2007) |
| "Eight patients who had had chronic dry eye disease for 3 to 20 years were treated with topical cyclosporine for 6 to 72 months, and then remained free of symptoms or signs of disease for at least 1 year (range, 16-29 months; mean, 21 months) after stopping treatment." | ( Perry, HD; Wilson, SE, 2007) |
| "The average score for the dry eye group was significantly increased compared with that for the nontreatment group at all time points throughout the experiment." | ( Hisamura, R; Imagawa, T; Masuda, N; Nakamura, S; Nakashima, H; Shibuya, M; Tsubota, K; Uehara, M, 2007) |
| "Patients with dry eye (N = 30) seen in a university-affiliated private practice were randomized to 1 of 3 treatments: cyclosporine 0." | ( Brazzo, BG; Carniglia, PE; Roberts, CW, 2007) |
| "All 3 regimens effectively treated dry eye." | ( Brazzo, BG; Carniglia, PE; Roberts, CW, 2007) |
| "Anti-inflammatory treatment of dry eye syndrome may include short-term corticosteroids, cyclosporine A emulsion, oral tetracycline therapy, oral omega-3 fatty acid supplements, and autologous serum eye drops." | ( Gierek-Ciaciura, S; Mrukwa-Kominek, E; Rogowska-Godela, A, 2007) |
| "36 patients with moderate to severe dry eye (5 mm/5 min or less with Schirmer's test or tear break up time (BUT) less than 6 seconds), were treated with topical application of CS-HA on one eye and CsA on the other 4 times a day for 6-8 weeks." | ( Kim, MK; Lee, HJ; Lee, JH; Moon, JW; Shin, KC; Wee, WR, 2007) |
| "Variability in the presentation of dry eye can hinder the observation of treatment effects." | ( Kim, T; Mah, FS; O'Brien, T; Torkildsen, G, 2008) |
| "Patients with dry eye disease (N = 6) defined by an Ocular Surface Disease Index symptom score >or=25, Schirmer test 1 <10 mm, and corneal fluorescein and conjunctival lissamine green staining scores >or=3 were treated with artificial tears (Refresh Plus; Allergan, Irvine, CA) 4 times a day for 4 weeks, followed by 0." | ( De Paiva, CS; Pflugfelder, SC; Stern, ME; Villarreal, AL, 2008) |
| "On treating dry eye model with nimesulide 0." | ( El-Gohary, AA; El-Hossary, GG; El-Shazly, AH; El-Shazly, LH, 2008) |
| "Subjective and objective dry eye assessment was performed for the post-treatment control of lacrimal gland function." | ( Aebersold, D; Curschmann, J; Ghadjar, P; Goldblum, D; Greiner, R, 2008) |
| "A total of 150 patients with defined dry eye disease participated (50 in each treatment group)." | ( Choi, JS; Joo, CK; Kim, EC, 2009) |
| "The understanding of dry eye disease in both its clinical expression and underlying etiopathology has expanded over the past 10 years with implications for management and therapy." | ( Foulks, GN, 2008) |
| "Many patients with dry eyes remain untreated due to improper diagnoses." | ( Ajaiyeoba, A; Ajayi, BG; Akang, EE; Baiyeroju, AM; Bekibele, CO, 2010) |
| "Current dry eye treatment includes delivering comfort agents to the eye via drops, but low bioavailability and multiple administration continues to be a barrier to effective treatment." | ( Ali, M; Byrne, ME, 2009) |
| "The botulinum toxin B-induced dry eye mouse model is potentially useful in evaluating new dry eye treatment." | ( Chae, JJ; Chuck, RS; Hongyok, T; Li, L; Na, D; Shin, YJ, 2009) |
| "Twenty-one patients diagnosed with dry eye syndrome secondary to vernal keratoconjunctivitis (7 cases), atopic keratoconjunctivitis (8 cases), and ocular rosacea (6 cases) were treated twice a day with a 0." | ( Denoyer, A; Nochez, Y; Pisella, PJ, 2009) |
| "A total of 30 Taiwanese patients with dry eye syndrome were included and randomly assigned to the 2 treatment groups: the mean (SD) age was 40." | ( Chou, HC; Ho, JD; Huang, MC; Lin, SY; Wang, IJ; Wang, TJ, 2010) |
| "To assess the prognosis of dry eye in patients treated with cyclosporine 0." | ( Rao, SN, 2010) |
| "The efficacy of hormone therapy (HT) on dry eye syndrome remains debatable." | ( Kaewrudee, S; Luanratanakorn, P; Piwkumsribonruang, N; Somboonporn, W; Soontrapa, S; Tharnprisan, P, 2010) |
| "Treatment of patients with dry eye for 6 months with topical cyclosporine A resulted in an increase in Schirmer test results, an increase in BUT scores, and an improvement in cytological grade of the disease." | ( Gülbahçe, R; Hoşal, BM; Sahli, E; Ustün, H; Zilelioğlu, G, 2010) |
| "Signs and symptoms of dry eye were compared along 28 days of treatment." | ( Baumane, K; Laganovska, G; Pirondini, C; Radecka, L; Ratiglia, R; Villani, E; Viola, F, 2011) |
| "Symptoms and signs of dry eye showed significant differences between the 2 groups after 2 and 4 weeks of treatment." | ( Baumane, K; Laganovska, G; Pirondini, C; Radecka, L; Ratiglia, R; Villani, E; Viola, F, 2011) |
| "As the signs and symptoms of dry eye disease worsened, the patient initiated therapy with once-daily hydroxypropyl cellulose ophthalmic inserts." | ( Wander, AH, 2011) |
| "To develop a dry eye model of mouse induced by topical administration of benzalkonium chloride (BAC) and investigate the possible mechanisms." | ( Bai, L; He, H; Lin, Z; Liu, X; Liu, Z; Wang, Y; Zhou, T, 2011) |
| "Use of long-term diclofenac sodium for dry eye after radiotherapy was possibly responsible for the spontaneous corneal perforation in our patient." | ( Demirel, S; Sarac, O, 2012) |
| "Eighteen patients with dry eye disease requiring medical therapy and/or punctal occlusion were recruited for this prospective, nonrandomized, observational case series." | ( Huang, D; Li, Y; Nguyen, P; Pappuru, RR; Ramos, S; Sadda, SR; Yiu, SC, 2012) |
| "To determine symptoms improvement in dry eye patients with short-term autologous serum (AS) eyedrops treatment using the standardized Ocular Surface Disease Index (OSDI) survey." | ( Alfaro, J; Hernandez, H; Huidobro, A; Urzua, CA; Vasquez, DH, 2012) |
| "Various types of dry eye treatment drugs have been developed." | ( Imanaka, T; Nakamura, M; Sakamoto, A, 2012) |
| "Diquafosol was effective in the treatment of dry eye disease at an optimal dose of 3% six times a day." | ( Imanaka, T; Nakamura, M; Sakamoto, A, 2012) |
| "Acupuncture treatment for dry eye may meet this requirement." | ( Miao, WH; Shi, JL, 2012) |
| "Nineteen control and 18 dry eye subjects used each product for 2 weeks, three times per day, in a random order, with a minimum 1-week washout between treatment periods." | ( Madden, LC; Simmons, PA; Tomlinson, A, 2013) |
| "Secondary subjective end points were dry eye-related ocular symptoms (foreign body sensation, dryness, photophobia, eye pain, and blurred vision) score and the patients' overall treatment impression score." | ( Awamura, S; Kinoshita, S; Nakamichi, N; Oshiden, K; Suzuki, H; Yokoi, N, 2013) |
| "Sixty-four patients with dry eye symptoms between the ages of 45 and 90 years were randomized into 2 groups: 33 persons in the treatment group and 31 persons in the placebo group." | ( Eftekhari, MH; Ghassemi-Broumand, M; Hashemi, H; Kangari, H; Khabazkhoob, M; Salamzadeh, J; Sardari, S, 2013) |
| "We assessed 12 subjective dry eye symptoms, corneal and conjunctival staining with fluorescein, tear film break-up time (BUT), lower tear meniscus height measured with anterior-segment optical coherence tomography, Schirmer's testing, and adverse reactions at baseline and 1, 3, and 6 months after the start of treatment." | ( Ikeda, C; Koh, S; Maeda, N; Nishida, K; Takai, Y; Watanabe, H, 2013) |
| "Treatment of mouse dry eye with osmoprotectants significantly reduced corneal staining on day 35 compared with day 21 (schedule 2)." | ( Chen, Q; Chen, W; Garrett, Q; Hou, C; Li, J; Wang, Y; Zhang, X, 2013) |
| "The application of AS in dry eye treatment has gained popularity as a second-line therapy in the treatment of dry eye." | ( Akpek, EK; Angelina, A; Heflin, T; Marrone, M; Pan, Q; Stark, WJ; Tang, L; Zambrano, A, 2013) |
| "In experimental dry eye disease, tofacitinib treatment twice per day significantly decreased corneal fluorescein staining on days 12 and 15." | ( Chauhan, SK; Dana, R; Hua, J; Huang, JF; Kodati, S; Sadrai, Z; Stevenson, W, 2014) |
| "The severity level of dry eye patients was classified based on the Korean guidelines for dry eye treatment." | ( Choi, C; Chung, E; Hyon, JY; Kim, HM; Lee, D; Lee, J; Song, JS, 2014) |
| "Similar dry eye signs or symptoms improved after 3 months of treatment reducing dryness, hyperemia, follicular hyperplasia, and foreign body sensation." | ( Figus, M; Fogagnolo, P; Frezzotti, P; Iester, M; Motolese, I; Perdicchi, A; Telani, S, 2014) |
| "In moderate to severe dry eye in Hansen's disease, serum therapy in comparison with AT drops, improves clinical parameters and causes betterment in tear protein profile." | ( Datta, H; Mukhopadhyay, S; Sen, S, 2015) |
| "Millions of Americans suffer from dry eye disease, and there are few effective therapies capable of treating these patients." | ( Aluri, SR; Gustafson, JA; Hamm-Alvarez, SF; Hsueh, PY; Jashnani, A; Laurie, GW; MacKay, JA; McKown, RL; Wang, W; Yarber, F, 2015) |
| "To compare the responses to dry eye treatment of patients sorted by the degree of lower lid laxity." | ( Lee, NY; Lyu, B; Oh, SH; Yim, HB, 2016) |
| "Nine patients with severe dry eye were treated with either RGN-259 (0." | ( Dunn, SP; Kim, C; Sosne, G, 2015) |
| "By considering two dry eye case scenarios, this review evaluates the currently available evidence relating to DED therapy to describe a pragmatic clinical approach to best-practice management of dry eye patients." | ( Downie, LE; Keller, PR, 2015) |
| "Current dry eye treatment includes delivering comfort enhancing agents to the eye via eye drops, but low residence time of eye drops leads to low bioavailability." | ( Maulvi, FA; Shah, DO; Soni, TG, 2015) |
| "Because of the high incidence of dry eye among postmenopausal women that may be related to the hormonal treatment, we propose that a multidisciplinary approach should be considered between gynecologists and ophthalmologists in management of this disorder." | ( Mircheff, AK; Sriprasert, I; Stanczyk, FZ; Warren, DW, 2016) |
| "This retrospective study included 38 dry eye patients (11 with SS and 27 with non-SS) who were treated with 3% diquafosol due to lack of response to artificial tear treatment for more than 3 months." | ( Hyon, JY; Jeon, HS, 2016) |
| "Eye diseases, such as dry eye syndrome, are commonly treated with eye drop formulations." | ( Ahmad, A; Boyd, S; Chang, CN; Dozois, MD; Gu, FX; Hileeto, D; Jones, LW; Liang, H; Liu, S; Ng, DL; Reyad, MM, 2016) |
| "Investigating normal and dry eye conditions through tear analysis may clarify the pathophysiology of dry eye conditions and support the efficacy of treatments." | ( Akune, Y; Shigeyasu, C; Yamada, M, 2016) |
| "At day three, following dry eye confirmation by corneal fluorescein staining (CFS, score 0-15) and phenol red thread (PRT) lacrimation test, the mice (n = 10/gp) were either treated 3 times a day in both eyes with drug-free cationic emulsion, a 0." | ( Antonelli, S; Barabino, S; Cimbolini, N; Daull, P; Feraille, L; Garrigue, JS; Mauro, V, 2016) |
| "To investigate dry eye development in the patients receiving systemic retinoic acid therapy and to compare effectiveness of Autologous Serum (AS) and preservative free artificial tear (PFAT) in the patients with dry eye disease." | ( Gökler, E; Koç, Ç; Küçük, E; Yılmaz, U, 2017) |
| "Patients detected as having dry eye during systemic isotretinoin treatment were included to our study." | ( Gökler, E; Koç, Ç; Küçük, E; Yılmaz, U, 2017) |
| "Successful treatment of dry eye should be aimed to restore the homeostasis of the ocular surface microenvironment." | ( Bu, J; He, X; Jia, C; Li, W; Liu, Z; M, VJ; Ou, S; Qu, Y; Wang, J; Wu, H; Zhang, X, 2017) |
| "In a rabbit dry eye model, corneal epithelial defects was ameliorated by treatment with single-dose administration of EGCG-containing GN." | ( Lai, JY; Luo, LJ, 2017) |
| "To compare the response of dry eye disease (DED) to treatment with topical steroid in patients with and without graft-vs-host disease (GVHD)." | ( Dana, R; Dohlman, T; Kheirkhah, A; Saboo, U; Yin, J, 2018) |
| "These drugs treat keratoconus and dry eye syndrome, respectively." | ( Aserin, A; Garti, N; Garti-Levy, S; Lidich, N, 2019) |
| "To determine the mucinogenic effect of dry eye (DE) treatment drugs currently in use, we compared the levels of mucin production and inflammatory cytokine expression on the ocular surfaces using a DE-induced mice model." | ( Ji, YW; Kang, HG; Kim, HC; Lee, HK; Moon, I; Noh, H; Song, JS; Yeo, A, 2018) |
| "Patients with severe dry eye disease (DED) often have limited treatment options with standard non-surgical management focused on the use of artificial tears for lubrication and anti-inflammatory drugs." | ( Ahmad, S; Balal, S; Barton, G; Bourne, RRA; Cook, E; Harrison, M; Hassan, A; Hayden, K; Pappas, Y; Pardhan, S; Sharma, A; Sharma, B; Udoh, A; Wasil, M, 2018) |
| "To do this, dry eye and corneal epithelial injuries were induced in rabbits by topical administration of atropine sulfate and NaOH." | ( Bermudez, MA; Eiro, N; Gonzalez, F; Martinez-Ordoñez, A; Perez-Fernandez, R; Saa, J; Sendon-Lago, J; Seoane, S; Vizoso, FJ, 2019) |
| "Following dry eye confirmation by corneal fluorescein staining (CFS), the mice were treated three times a day with: 0." | ( Barabino, S; Baudouin, C; Daull, P; Docquier, M; Feraille, L; Garrigue, JS; Kessal, K; Parsadaniantz, SM, 2019) |
| "Twenty patients with depression and dry eye disease (DED) were randomly picked to receive SSRI treatment, whereas another 20 patients received placebo treatment." | ( Gong, L; Yin, Y; Yue, L; Zhang, X, 2019) |
| "One of the key challenges in dry eye syndrome therapy is to find a suitable carrier for immunosuppressant drug - cyclosporine A (CsA) - delivery to the eye." | ( Chachaj-Brekiesz, A; Dynarowicz-Latka, P; Kobierski, J; Lipiec, E; Wnętrzak, A, 2019) |
| "In the treatment of dry eye disease, HA provides water retention and lubricant properties that challenge current treatment." | ( Huynh, A; Priefer, R, 2020) |
| "Addressing these will improve dry eye practice and treatment outcomes in the country." | ( Cox, SM; Nichols, KK; Osei, KA, 2020) |
| "The treatment of dry eye in these patients is difficult to manage, with topical immunomodulators such as cyclosporine A as a good alternative when lubricants are insufficient." | ( Botella García, J; de la Paz, MF; Lázaro-Rodríguez, V, 2022) |
| "Allergic conjunctivitis and dry eye syndrome are common ocular surface diseases that have been treated with traditional pharmacological measures, e." | ( Bielory, L; Tabliago, NRA, 2020) |
| "A literature review of published dry eye clinical trials was performed to identify the pivotal clinical trials of DED medications and to compare treatment effect and further understand the impact of the vehicle on clinical trial outcomes." | ( Evans, DG; Karpecki, PM; Nichols, KK, 2021) |
| "In our study, a BAC-induced dry eye rabbit model was treated with eye drops containing astragaloside IV (5, 10 μM) or solvent four times a day." | ( Cao, W; Chen, Z; Chu, L; Ma, S, 2021) |
| "The treatment of dry eye disease must be individualized, dynamic and optimized for each stage of the disease." | ( Zemanová, M, 2021) |
| "The present rabbit dry eye model study demonstrated potentials of topically administered 0." | ( Wang, M; Wang, Z; Yu, L; Zhang, S, 2022) |
| "The effectiveness of the OAS dry eye model in NZW rabbits as reported in previous studies was confirmed, provided that the application of the drug is maintained throughout the intervention; it is not a viable model after OAS administration is suspended." | ( Baiza-Durán, L; Correa-Gallegos, EY; Medina-Espinoza, JM; Muñoz-Villegas, P; Navarro-Sanchez, AA; Olvera-Montaño, O; Sánchez-Ríos, A, 2022) |
| "Early treatments of dry eye and collaborations among multidisciplinary physicians are necessary in patients with AIBD." | ( Feng, J; He, Y; Kang, H; Liu, Y; Peng, Y; Ren, Y; Shi, W; Tan, Y; Wu, M; Wu, R; Zhang, G, 2022) |
| "Medical records of 188 patients with dry eye after phacoemulsification, treated in our hospital from August 2020 to August 2021, were included and divided into groups based on the type of dry eye treatment." | ( Guan, Y; Lu, H; Nan, N; Su, Y; Yuan, Y, 2022) |
| "Medical records of 188 patients with dry eye after phacoemulsification, treated in our hospital from August 2020 to August 2021, were included and divided into groups based on the type of dry eye treatment." | ( Guan, Y; Lu, H; Nan, N; Su, Y; Yuan, Y, 2022) |
| "There is a clinical necessity for dry eye disease treatments that perform across a broad range of presenting patient severities." | ( Blemker, G; Gibson, A; Hemphill, M; Hendrix, LH; Karpecki, PM; Macsai, M; O'Dell, LE; Raizman, MB; Sheppard, JD; Whitley, WO, 2023) |
| "To study the incidence of dry eye disease (DED) in head and neck cancer (HNC) patients undergoing external beam radiotherapy (EBRT), to find a correlation between tumor location and total radiation dose with DED, and to report various radiotherapy (RT) induced acute toxic effects on ocular and adnexal structures." | ( Jain, P; Soni, M; Walia, S, 2023) |
| "The treatment of dry eye mainly includes instillation of cyclosporine A (CsA) nanoemulsion or the use of punctal plugs." | ( Bai, S; Cao, Z; Chen, Y; Gui, S; He, N; Liu, Y; Shan, S; Wu, J; Zheng, Z, 2023) |
| "To identify specific dry eye disease (DED) tear biomarker(s) using tear proteomic analysis, clinical parameters, and their correlations before and after DED treatment." | ( An, WJ; Choi, CY; Chung, TY; Jeon, S; Jeong, SJ; Jung, GT; Kim, HS; Kim, KP; Kim, M; Kim, TI; Lee, HK; Lee, HS; Song, JS, 2023) |
| "affine, as a novel treatment for dry eye disease (DED)." | ( Ahn, KS; Chung, JH; Jang, HJ; Ko, JH; Oh, JH; Oh, JY; Oh, SR; Ryu, JS; Yoon, CH, 2023) |
| "A mouse model of dry eye was established by administering with BAC to BALB/c mice, and the expression of TNF-α, IL-1β, IL-6, IL-8, cyclooxygenase 2 (COX2), interleukin-1 receptor-associated kinase 1 (IRAK1) and TNF receptor-associated factor 6 (TRAF6) in the corneas of dry eye model mice was significantly increased; this was accompanied by the upregulation of miR-146a and activation of the NF-κB pathway." | ( Chen, X; Gao, J; Han, R; Hao, P; Jiang, L; Jiang, Z; Li, X; Wang, L; Wang, T; Wang, Y; Zhu, L, 2023) |
| "A total of 126 patients (126 eyes) with dry eye syndrome after cataract surgery were treated between January 2021 and October 2022." | ( Fu, J; Jia, Q; Zhao, X, 2023) |
| "Differentiating dry eye disease (DED) from allergic or viral conjunctivitis rapidly and accurately is important to ensure prompt diagnosis and treatment." | ( Tang, H; Yan, P; Zhang, J; Zhang, Y, 2023) |
| "Although dry eye disease (DED) is one of the most common ocular surface diseases worldwide, its pathogenesis is incompletely understood, and treatment options are limited." | ( De Goüyon Matignon de Pontourade, CMF; Keller, I; Lincke, JB; Schlegel, I; Zinkernagel, MS; Zysset-Burri, DC, 2023) |